Skeletal muscle has proved to be very difficult to grow in patients with muscular dystrophy and other disorders that degrade and weaken muscle. Researchers at Boston Children's Hospital's Stem Cell Program now report boosting muscle mass and reversing disease in a mouse model of Duchenne muscular dystrophy, using a "cocktail" of three compounds identified through a new rapid culture system. Adding the same compounds to stem cells derived from patients' skin cells, they then successfully grew human muscle cells in a dish.
Senior investigator Leonard Zon, MD, director of the Stem Cell Program at Boston Children's and an investigator with the Howard Hughes Medical Institute, hopes for clinical trials to begin transplanting these cells into patients with muscle loss in the next several years. In the meantime, the screening technique, described in the journal Cell (published online November 7), can also be applied to multiple disorders beyond muscular dystrophy, he says.
The drug screening technique begins with zebrafish. Zon and colleagues placed tiny zebrafish blastomeres--cells from very early stage embryos--into 384-well culture dishes, adding one test compound to each well. This allowed them to screen 2,400 compounds at once, seeking ones that boosted numbers of muscle progenitor cells in the see-through fish as they developed.
The Zon Lab's earlier work with zebrafish led to a drug derived from prostaglandin that expands numbers of blood stem cells and is now in a Phase II clinical trial. But this time, researchers genetically modified the fish so that newly created muscle progenitor cells would show up in fluorescent green, and muscle fibers in red. This enabled the team to rapidly quantify muscle cells and fibers produced under different conditions, based on visual readouts--without having to examine each well's contents through laborious biochemical techniques.
"Automated imagers can take a picture to assay all the 384 wells within a matter of a week, as compared with several months with our earlier technique," says Zon, who is also a member of Boston Children's Division of Hematology/Oncology as well as the Harvard Stem Cell Institute (HSCI).
The zebrafish tests revealed six compounds that expanded numbers of skeletal muscle progenitor cells. The Zon Lab collaborated with Amy Wagers, PhD, of HSCI and the Joslin Diabetes Center, and C. Ronald Kahn, MD, of Joslin to conduct experiments in a mouse model of Duchenne muscular dystrophy. "One of our chemicals, forskolin, also increased engraftment of progenitors into the muscles of the mice," Zon says. "We found you could get more muscle mass just by making more progenitors."
(Forskolin, though not approved by the FDA, has been used since ancient times to treat a variety of disorders and is sold as a dietary supplement.)
3# Patient-specific cells
Zon, Wagers, Kahn and colleagues next turned to human cells in a dish, working with induced pluripotent stem cells (iPS cells) made from the skin cells of patients with Duchenne muscular dystrophy. "Many muscle diseases could not be adequately modeled in iPS cells in the past," notes Zon. "No one's been able to get iPS cells to form skeletal muscle."
The researchers found that a combination of three small molecules (forskolin, basic fibroblast growth factor and a glycogen synthase kinase-3 GSK-3beta inhibitor) was able to reprogram iPS cells into muscle cells that successfully engrafted in mice.
Zon's next goal is to transplant these muscle cells from the dish into patients through clinical trials he hopes develop within the next several years. He may begin by trying to increase muscle mass in a specific anatomic location, but for a condition like Duchenne muscular dystrophy, he envisions a series of local injections in different parts of the body.
Zon believes that the combination of rapid zebrafish screening with patient-specific iPS cells will greatly speed up therapeutic development, allowing scientists to quickly vet large numbers of compounds and possible culture conditions. They can then enter a much shorter list of compounds into lengthier testing in human iPS cells that recapitulate the disease in question, as well as live mouse models.
"It's been very hard to figure out the conditions for making different tissues with iPS cells," Zon says. "We've created a very fast system to find what chemicals you need. Because it's so fast, we don't need a hypothesis to do an experiment--you can just do the screen, find the result and see what warrants pursuing."
The zebrafish system can also quickly spot inhibitors of tissue growth; in fact, it grew out of the lab's desire to find chemicals that blocked muscle development to treat rhabdomyosarcoma, a tumor that grows in skeletal muscle. The Zon Lab is also using it to find chemicals that can block expansion of melanocytes, potentially halting melanoma.
Using these technologies, the Zon Lab has developed and filed a patent on a platform for large-scale chemical screening in zebrafish. The lab has also benefited from funding from the Massachusetts Life Sciences Center.
Cong Xu of HSCI and Boston Children's Hospital, Mohammadsharif Tabebordbar of HSCI and Harvard University, and Salvatore Iovino of the Joslin Diabetes Center and Harvard Medical School shared first authorship of the paper. Funders included the National Institutes of Health (NIH #5P30 DK49216-19, #5R01CA103846-10, #DP2OD004345, #UO1HL100402, #DK31036), the Harvard Stem Cell Institute and the Howard Hughes Medical Institute. Zon is a founder and stockholder of Fate, Inc. and a scientific advisor for Stemgent.
Boston Children's Hospital is home to the world's largest research enterprise based at a pediatric medical center, where its discoveries have benefited both children and adults since 1869. More than 1,100 scientists, including seven members of the National Academy of Sciences, 14 members of the Institute of Medicine and 14 members of the Howard Hughes Medical Institute comprise Boston Children's research community. Founded as a 20-bed hospital for children, Boston Children's today is a 395-bed comprehensive center for pediatric and adolescent health care grounded in the values of excellence in patient care and sensitivity to the complex needs and diversity of children and families. Boston Children's is also the primary pediatric teaching affiliate of Harvard Medical School. For more information about research and clinical innovation at Boston Children's, visit: http://vectorblog.org.
[Note to reporters: A color image of muscle tissue developing in zebrafish is available on request.]
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.